Adalimumab as Treatment for Venous Thrombosis in Behçet's Syndrome: Comment on the Article by Emmi et al

Göster/Aç
Tarih
2019-03-02
Yazar
Farisogullari, Bayram
Sari, Alper
Ayar, Sefika Nur
Kilic, Levent
Armagan, Berkan
Karadağ, Ömer
Üst veri
Tüm öğe kaydını göster
Özet
We read with interest the article by Emmi et al 1 regarding the effect of adalimumab (ADA)–based treatment versus disease‐modifying antirheumatic drug (DMARD) therapy for venous thrombosis in Behçet's syndrome (BS). Their findings add important data to help answer the difficult questions on the treatment of BS. However, there are some concerns.
Bağlantı
https://doi.org/10.1002/art.40795
https://pubmed.ncbi.nlm.nih.gov/30548210/
https://onlinelibrary.wiley.com/doi/epdf/10.1002/art.40795
http://hdl.handle.net/11655/23569
Koleksiyonlar
Künye
Farisogullari B, Sari A, Ayar SN, Kilic L, Armagan B, Karadag O. Adalimumab as Treatment for Venous Thrombosis in Behçet's Syndrome: Comment on the Article by Emmi et al. Arthritis Rheumatol. 2019 Apr;71(4):657. doi: 10.1002/art.40795. Epub 2019 Mar 2. PMID: 30548210.

Aşağıdaki lisans dosyası bu öğe ile ilişkilidir:

info:eu-repo/semantics/openAccess
Aksi belirtilmediği sürece bu öğenin lisansı: info:eu-repo/semantics/openAccess